エンチノスタット(MS-27-275)
エンチノスタット(MS-27-275) 物理性質
- 融点 :
- 159-160 ºC
- 沸点 :
- 566.7±50.0 °C(Predicted)
- 比重(密度) :
- 1.315
- 貯蔵温度 :
- Keep in dark place,Sealed in dry,Store in freezer, under -20°C
- 溶解性:
- DMSO: 38 mg/mL、可溶
- 外見 :
- 個体
- 酸解離定数(Pka):
- 11.32±0.46(Predicted)
- 色:
- ペールイエロー
- 安定性：:
- -20°C の DMSO 溶液で最大 1 週間保存できます。
- InChIKey:
- INVTYAOGFAGBOE-UHFFFAOYSA-N
エンチノスタット(MS-27-275) 価格
もっと(13)
| メーカー |
製品番号 |
製品説明 |
CAS番号 |
包装 |
価格 |
更新時間 |
購入 |
|
富士フイルム和光純薬株式会社(wako)
|
W01LKTE5477 |
Entinostat |
209783-80-2 |
100mg |
￥174300 |
2024-03-01 |
購入 |
|
富士フイルム和光純薬株式会社(wako)
|
W01CAY13284 |
MS-275 |
209783-80-2 |
1mg |
￥5900 |
2024-03-01 |
購入 |
|
富士フイルム和光純薬株式会社(wako)
|
W01CAY13284 |
MS-275 |
209783-80-2 |
25mg |
￥48200 |
2024-03-01 |
購入 |
|
富士フイルム和光純薬株式会社(wako)
|
W01LKTE5477 |
エンチノスタット
Entinostat |
209783-80-2 |
1mg |
￥8700 |
2024-03-01 |
購入 |
|
富士フイルム和光純薬株式会社(wako)
|
W01LKTE5477 |
エンチノスタット
Entinostat |
209783-80-2 |
5mg |
￥21800 |
2024-03-01 |
購入 |
エンチノスタット(MS-27-275) 化学特性,用途語,生産方法
効能
抗悪性腫瘍薬, ヒストン脱アセチル化酵素阻害薬
説明
Entinostat (SNDX-275, MS-275) belongs to benzamide class HDACi and inhibits HDAC1 and 2, 3 and 9 and has low effect against HDAC4, 6, 7 and 8 (Khan et al. 2007). Entinostat is in phase II clinical trial for treatment of Hodgkin's lymphoma and advanced breast cancer (in combination with aromatase inhibitors) and metastatic lung cancer (in combination with erlotinib).
化学的特性
Yellow Solid
定義
ChEBI: A member of the class of benzamides resulting from the formal condensation of the carboxy group of the pyridin-3-ylmethyl carbamate derivative of p-(aminomethyl)benzoic acid with one of the amino groups of benzene-1,2-diamine. It is an inhibit
r of histone deacetylase isoform 1 (HDAC1) and isoform 3 (HDAC3).
臨床応用
Entinostat is an HDAC inhibitor with a relatively long half-life (averaging between 33 and 52 hours). Trials have shown significant biological activity in patients with hematological malignancies receiving entinostat treatments. However, the efficacy of entinostat as a single-agent therapy remains limited. Reported dose-limiting toxicities associated with entinostat include neurotoxicity, fatigue, hypophosphatemia, anorexia, and vomiting.
The large number of clinical trials using HDAC inhibitors for the treatment of patients with hematological malignancies has demonstrated that these drugs are relatively well tolerated. Although the responses with the currently-available HDAC inhibitors are still limited, there are significant responses in some patients with advanced disease, where options are limited. With better patient selection and the development of more potent HDAC inhibitors, targeting HDACs for the treatment of hematological malignancies remains promising. Furthermore, a growing body of literature suggests that HDAC inhibitors may potentiate some of the currently used cytotoxic or biologic therapies based on their mechanism of action, with multiple trials currently ongoing. Promising combination partners include proteosome inhibitors, DNA demethylating agents, and anthracyclines.
エンチノスタット(MS-27-275) 上流と下流の製品情報
原材料
準備製品
エンチノスタット(MS-27-275) 生産企業
Global( 225)Suppliers
エンチノスタット(MS-27-275) スペクトルデータ(MS)
209783-80-2(エンチノスタット(MS-27-275))キーワード:
- 209783-80-2
- Carbamic acid, N-[[4-[[(2-aminophenyl)amino]carbonyl]phenyl]methyl]-, 3-pyridinylmethyl ester
- entinostat
- 3-pyridinylmethyl [[4-[[(2-aminophenyl)amino]carbonyl]phenyl]methyl]carbamate, N-(2-Aminophenyl)-4-[N-(pyridine-3ylmethoxycarbonyl)aminomethyl]benzamide
- N-[[4-[[(2-Aminophenyl)amino]carbonyl]phenyl]methyl]carbamic acid 3-pyridinylmethyl ester
- Entinostat/MS-275
- Nsc706995
- Entinostat(NSC-706995)
- (Pyridin-3-yl)Methyl 4-(2-AMinophenylcarbaMoyl)benzylcarbaMate
- MS 275-27
- MS-275,Entinostat,SNDX-275
- MS-275 (Entinostat)
- Entinostat (MS-275,SNDX-275)
- [4-(2-Amino-phenylcarbamoyl)-benzyl]-carbamic acid pyridin-3-ylmethyl ester
- Entinostat
N-[[4-[[(2-Aminophenyl)amino]carbonyl]phenyl]methyl]carbamic acid 3-pyridinylmethyl ester
- N-[[4-[[(2-Aminophenyl)amino]carbonyl]phenyl]methyl]carbamic acid 3-pyridinylmethyl ester Entinostat (MS-275, SNDX-275)
- entinostat(HDAC inhibitor)
- Entinostat, >=98%
- Entinostat
(MS-27-275)
- entinostat side effects
- MS 2275
- Entinostat USP/EP/BP
- MS275; SNDX 275
- CS-189
- MS275;MS 275
- Rivipansel
- Entenot
- エンチノスタット(MS-27-275)
- エンチノスタット
- エンチノスタット, FREE BASE
- MS-275 (エンチノスタット, SNSNDX-275
- エンチノスタット (JAN)
- N-(2-アミノフェニル)-4-[[(3-ピリジルメトキシ)カルボニルアミノ]メチル]ベンズアミド
- MS-275
- [4-[(2-アミノフェニル)カルバモイル]ベンジル]カルバミド酸3-ピリジルメチル
- N-[4-[[(2-アミノフェニル)アミノ]カルボニル]ベンジル]カルバミド酸(3-ピリジニル)メチル
- (ピリジン-3-イル)メチル N-({4-[(2-アミノフェニル)カルバモイル]フェニル}メチル)カルバマート